Alabama Schedules Hearing on Marijuana Rescheduling After Federal Move

Alabama Board Sets August Hearing Date

The Alabama Board of Medical Examiners set an August 15, 2026 hearing to consider rescheduling marijuana under state law. The board published notice of the hearing in the Alabama Administrative Monthly on July 19, according to the state register. Public comment will be accepted through August 10.

The hearing follows the Drug Enforcement Administration's final rule, effective June 1, 2026, that reclassified cannabis as a Schedule III controlled substance. Alabama's Uniform Controlled Substances Act currently mirrors the federal scheduling framework but requires state action to adopt federal changes.

Federal Rescheduling Creates State-Level Pressure

Twenty-three states maintain controlled substance schedules that automatically adopt federal classifications, but Alabama requires administrative or legislative action to align state and federal schedules. The gap creates legal uncertainty for Alabama's medical cannabis program, which launched dispensary sales in March 2025.

Alabama Medical Cannabis Commission Executive Director John McMillan said in a July 18 statement that the commission requested the hearing to clarify the regulatory framework for licensed operators. The state issued 12 dispensary licenses and four cultivation licenses under the 2021 medical cannabis law.

The federal rescheduling doesn't automatically change Alabama law, but it creates operational questions for licensed entities that the hearing is designed to address.

Tax and Banking Implications for Alabama Operators

Federal rescheduling to Schedule III eliminates Internal Revenue Code Section 280E tax penalties, but Alabama's state tax treatment depends on how the state classifies cannabis. Alabama currently imposes a 9 percent excise tax on medical cannabis sales plus standard sales tax. Operators have paid an estimated $4.2 million in state taxes since dispensaries opened, according to commission data through June 2026.

If Alabama adopts Schedule III classification, state-licensed operators would gain clarity on banking access and interstate commerce questions. Federal rescheduling opened pathways for cannabis businesses to access traditional banking services and Small Business Administration loans, but state-level misalignment complicates those benefits in states like Alabama.

Legislative History and Prior Attempts

Alabama's General Assembly considered but didn't advance legislation in the 2026 session that would have automatically synchronized state scheduling with federal changes. House Bill 287, sponsored by Rep. Mike Ball (R-Madison), died in the House Judiciary Committee in May without a vote.

Ball, who authored Alabama's 2021 medical cannabis law, said the administrative hearing route may prove faster than waiting for the 2027 legislative session. The Alabama Board of Medical Examiners has statutory authority under Alabama Code § 20-2-23 to add, delete, or reschedule substances by rule if it finds the action consistent with federal scheduling and public health standards.

What Comes Next for Alabama Cannabis Policy

The August 15 hearing will include testimony from the Medical Cannabis Commission, law enforcement representatives, and licensed operators. The board must issue a final decision within 60 days of the hearing close. If the board adopts Schedule III classification, the rule change would take effect 35 days after filing with the Legislative Services Agency.

For full background on this story, see the CannIntel topic hub on Alabama cannabis rescheduling. Alabama remains one of 15 states with active medical programs but no adult-use framework. Rescheduling at the state level wouldn't expand patient access or product types but would resolve the federal-state classification gap that's created compliance uncertainty since June.